Title: Inhibitory effect of epristeride on the expression of prostate specific antigen and Bcl-2 protein in human prostatic carcinoma LNCaP cells in vitro
Abstract: AIM To investigate the possibility of treating prostate carcinoma with epristeride and its possible mechanisms. METHODS The prostate carcinoma LNCaP cells were treated with epristeride for 3 d or 7 d. Cell morphology was observed under phase-contrast microscope, cell viability was detected by trypan blue method. Apoptosis was detected by flow cytometer, the expressions of prostate specific antigen(PSA) and Bcl-2 protein were detected by immunohistochemical method. RESULTS Epristeride inhibited the growth of human prostatic cancer LNCaP cells with the inhibition rate of 40.0%, 47.4% and 54.3% when exposed to 5, 15 and 45 μmol·L -1 epristeride for 7 d, respectively. The epristeride in the three concentrations induced apoptosis in the LNCaP cells with the apoptosis rate of 3.5%, 15.8% and 25.0%, respectively, and the apoptosis rate in the control group was 2.2%. The epristeride dose-dependently decreased the expression of PSA and Bcl-2 protein in the LNCaP cells. CONCLUSION Epristeride is able to inhibit the growth and the expression of PSA and Bcl-2 protein of human prostate carcinoma cell line LNCaP, thus inducing apoptosis in LNCaP cells in the three concentrations in vitro.
Publication Year: 2003
Publication Date: 2003-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot